Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine vs Tacrolimus for NODM in Kidney Transplant
NCT00171496Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2003
- Primary completion
- Mar 2006
- Modality
- Peptides, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of cyclosporine in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoints: Incidence of New Onset Diabetes Mellitus or Impaired Fasting Glucose at 6 months and Incidence of Biopsy-Proven Acute Rejection, Graft Loss, or Death at 6 months. Started Oct 2003; status: completed.
02
Drugs
cyclosporine
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00171496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171496.